- Home
- BCG vs TENX Comparison
BCG vs TENX Comparison
Compare BCG & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- TENX
- Stock Information
- Founded
- BCG 2016
- TENX 1967
- Country
- BCG United States
- TENX United States
- Employees
- BCG N/A
- TENX N/A
- Industry
- BCG
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- BCG
- TENX Health Care
- Exchange
- BCG Nasdaq
- TENX Nasdaq
- Market Cap
- BCG 29.6M
- TENX 27.3M
- IPO Year
- BCG N/A
- TENX N/A
- Fundamental
- Price
- BCG $2.15
- TENX $6.98
- Analyst Decision
- BCG
- TENX Strong Buy
- Analyst Count
- BCG 0
- TENX 3
- Target Price
- BCG N/A
- TENX $16.67
- AVG Volume (30 Days)
- BCG 48.6K
- TENX 131.1K
- Earning Date
- BCG 11-13-2025
- TENX 11-12-2025
- Dividend Yield
- BCG N/A
- TENX N/A
- EPS Growth
- BCG N/A
- TENX N/A
- EPS
- BCG N/A
- TENX N/A
- Revenue
- BCG $173,961,000.00
- TENX N/A
- Revenue This Year
- BCG N/A
- TENX N/A
- Revenue Next Year
- BCG N/A
- TENX N/A
- P/E Ratio
- BCG N/A
- TENX N/A
- Revenue Growth
- BCG 7.45
- TENX N/A
- 52 Week Low
- BCG $1.45
- TENX $3.61
- 52 Week High
- BCG $6.55
- TENX $8.24
- Technical
- Relative Strength Index (RSI)
- BCG 70.00
- TENX 49.60
- Support Level
- BCG $1.54
- TENX $7.49
- Resistance Level
- BCG $2.20
- TENX $7.73
- Average True Range (ATR)
- BCG 0.13
- TENX 0.41
- MACD
- BCG 0.06
- TENX -0.06
- Stochastic Oscillator
- BCG 88.73
- TENX 14.61
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.